Boceprevir and HIV Drug Can Interact Dangerously | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Hep C Bulletin: Medication Management

Back to News Homepage
Next

Triple Therapy with GS-7977 Successful Against Hepatitis C

Boceprevir and HIV Drug Can Interact Dangerously

The Editors at Hepatitis Central
May 1, 2012

Print this page

Of concern to those co-infected with Hepatitis C and HIV, the FDA has confirmed that the Hep C drug, boceprevir, interferes with the HIV drug, ritonavir.

FDA: Don’t Mix New HCV Drug with HIV Drugs

By Michael Smith, North American Correspondent, MedPage Today

Published: April 26, 2012

The FDA has issued a warning against using boceprevir (Victrelis) and anti-HIV drugs that contain the protease inhibitor ritonavir (Norvir) because of possibly dangerous drug interactions.

But the agency cautioned that patients already taking boceprevir and one of the HIV regimens containing ritonavir should not stop their medications without consulting their doctors.

Physicians with patients taking boceprevir and any HIV regimen containing ritonavir should monitor them carefully to ensure that:

  • Hepatitis C treatment response – defined as no virus detected in the blood – continues.
  • Hepatitis C or HIV virologic rebound — defined as either virus detected in the blood again after previously being undetectable — does not occur.

Continue reading this entire article:
http://www.medpagetoday.com/InfectiousDisease/Hepatitis/32377

No Comments - be the first!
Share
Share
Previous

Hep C Bulletin: Medication Management

Back to News Homepage
Next

Triple Therapy with GS-7977 Successful Against Hepatitis C

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.